[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560066":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":32,"responsibleParty":49,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of South Florida","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Continuous glucose monitoring cohort (intervention)",null,"Freestyle libre 2 or 3+ sensor devices will be used to monitor glucose. The sensors are worn on the upper arm and changed every 14 (libre 2) or 15 (libre 3+) days. Each subject will have 5 visits with a pharmacist over 12 weeks. Subjects meeting inclusion criteria will include adults ≥18 years of age with type 2 diabetes and a hemoglobin A1c ≥ 8%. Subjects must have a compatible smartphone with the freestyle libre 2 sensor system. Subjects must have access to a glucometer to check blood glucose. Subjects must not have worn a continuous glucose monitor in the last 6 months to be eligible.",[13],"Device: FreeStyle Libre 2\u002FLibre 3+ Continuous Glucose Monitor",{"label":15,"type":10,"description":16,"interventionNames":10},"Self-monitoring of blood glucose cohort (historical cohort)","A retrospective chart review will be performed on patients seen by a clinic pharmacist between 1\u002F1\u002F2020-7\u002F1\u002F2024. Subjects in this group will include adults ≥18 years of age with type 2 diabetes and a hemoglobin A1c ≥ 8% and using a glucometer to monitor blood sugar. Exclusion criteria will be use of any continuous glucose monitoring device within the prior 6 months of the index date (defined as first visit with a pharmacist during study time frame).",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DEVICE","FreeStyle Libre 2\u002FLibre 3+ Continuous Glucose Monitor","Subjects included in the intervention group (continuous glucose monitoring) will be recruited from the USF Health Department of Family Medicine. Each subject will be enrolled for 12 weeks.",[9],[24],{"name":25,"affiliation":5,"role":26},"Kevin Cowart, PharmD, MPH","PRINCIPAL_INVESTIGATOR",[28],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","813-974-5562","kcowart2@usf.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"USF Health Department of Family Medicine","RECRUITING","Tampa","Florida","33612","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-82.45843,27.94752,{"lat":45,"lon":44},[48],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},{"type":26,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Kevin Cowart","Associate Professor","100560066","pharmacist-led-continuous-glucose-monitoring-100560066",false,"NCT06572306","Pharmacist-led Continuous Glucose Monitoring","Investigating the Impact of Pharmacist-led Flash Continuous Glucose Monitoring on Clinical and Behavioral Health Outcomes","Inclusion Criteria:\n\n* type 2 diabetes\n* hemoglobin A1c ≥ 8%\n* compatible smartphone with FreeStyle Libre 2 or Libre 3+ continuous glucose monitoring system\n* current use and access to a glucometer for self-monitoring of blood glucose\n\nExclusion Criteria:\n\n* any continuous glucose monitor use within 6 months prior to study enrollment\n* pregnant and planning to become pregnant during study time frame\n* history of hypoglycemia requiring third party assistance\n* history of diabetic ketoacidosis or hyperosmolar hyperglycemic state within 6 months prior to study enrollment\n* known allergy to medical grade adhesives\n* current use of systemic steroids for any medical condition\n* current use of dialysis","ALL","18 Years",{"count":62,"type":63},40,"ESTIMATED","OBSERVATIONAL","This is a pilot study. The goal of this prospective cohort study is to determine impact of pharmacist-led continuous glucose monitoring on glycemic control and health behavior change in people with type 2 diabetes. The main questions it aims to answer are:\n\n1. to assess change in hemoglobin A1c in people with type 2 diabetes using continuous glucose monitoring under a pharmacist-led approach as compared to a pharmacist-led approach utilizing no continuous glucose monitoring (only self-monitoring blood glucose with a glucometer).\n2. to assess change in continuous glucose monitoring-derived glycemic outcomes among the pharmacist-led continuous glucose monitoring cohort (intervention group)\n3. to assess change in health behavior among the pharmacist-led continuous glucose monitoring cohort (intervention group)",[67],"Type 2 Diabetes",[69,70,71,72],"type 2 diabetes","endocrine disorders","continuous glucose monitor","pharmacist","2026-04-17",{"date":75,"type":76},"2026-04-22","ACTUAL",{"date":78,"type":76},"2024-09-01",{"date":80,"type":63},"2026-06-30",{"name":5,"class":6},1]